Disordered haematopoiesis and athero-thrombosis
Disordered haematopoiesis and athero-thrombosis
复制标题
DOI：
10.1093/eurheartj/ehv718
复制
发表时间：
2016-04-07
影响因子：
39.3
通讯作者：
Tall, Alan R.
中科院分区：
文献类型：
--
作者：
Murphy, Andrew J.;Tall, Alan R.
动脉粥样硬化是心血管疾病的主要潜在原因，其特征是在大动脉和中动脉中脂质驱动的炎症细胞浸润。在高胆固醇血症和高密度脂蛋白介导的胆固醇外排缺陷、心肌梗死后组织坏死和细胞因子产生或糖尿病相关代谢异常的驱动下，单核细胞、中性粒细胞和血小板的产生和激活增加，有助于动脉粥样硬化和动脉粥样硬化血栓形成。这表明，除了传统的低密度脂蛋白降低方法和抗血小板药物外，针对异常造血的治疗，包括抗炎药、抑制骨髓生成的药物、过度血小板产生的药物、rHDL输注、抗肥胖和抗糖尿病药物，可能有助于预防动脉粥样硬化血栓形成。
Atherosclerosis, the major underlying cause of cardiovascular disease, is characterized by a lipid-driven infiltration of inflammatory cells in large and medium arteries. Increased production and activation of monocytes, neutrophils, and platelets, driven by hypercholesterolaemia and defective high-density lipoproteins-mediated cholesterol efflux, tissue necrosis and cytokine production after myocardial infarction, or metabolic abnormalities associated with diabetes, contribute to atherogenesis and athero-thrombosis. This suggests that in addition to traditional approaches of low-density lipoproteins lowering and anti-platelet drugs, therapies directed at abnormal haematopoiesis, including anti-inflammatory agents, drugs that suppress myelopoiesis, and excessive platelet production, rHDL infusions and anti-obesity and anti-diabetic agents, may help to prevent athero-thrombosis.